TheiaLife signs Agreement with LifeSci Consulting for transaction advisory services for strategic partnering initiatives

April 3, 2023

Theialife is an innovative clinical stage virtual biopharmaceutical company focused on the discovery and development of novel drugs for Ophthalmology applications. Its first product, 7-MX, is a first-in-class oral therapy for the treatment and management of Myopia progression in children.

Following a Phase 2 clinical trial, the Danish Medicines Agency approved pharmacy compounded tablets of 7-MX for preventing myopia progression in children and granted reimbursement with Danish National Health Insurance. As of July 2022, 1,171 patients have been prescribed 7-MX with no reported adverse effects, and over 200 patients continue to be treated. A Global phase III Clinical Trial is in planned for late 2023 / early 2024

Theialife’s collaboration with LifeSci Consulting follows strong third-party interest in initiating collaboration discussions surrounding Theialife’s 7-MX asset.

“We are pleased to have seen interest in collaborations rise after Theialife’s Denmark Real world experience of 7-MX was published in the British Journal of Ophthalmology last year. Securing licensing agreements and a variety of collaborations for 7-MX is an essential part of Theialife’s business strategy, and we are excited to be working with a leading life science transaction advisory firm such as LifeSci Consulting to help us secure a strategic transaction. While completion of any transactions is not assured, we look forward to beginning our collaboration with LifeSci Consulting and exploring partnering opportunities,” says Mr Sundeep Aurora, Director of Theialife Sciences.

“Theialife is developing a novel treatment to solve Myopia, an indication having a significant unmet medical need as treatment options are extremely limited. This collaboration will enhance Theialife’s ability to identify ideal partners and ultimately generate long-term value for patients. With 5,000+ global industry contacts and $8B total deal value, our team is well-positioned to provide Theialife with impactful strategic counsel to support optimum strategic transactions. The clinical results generated by Theialife are impressive and we look forward to presenting 7-MX to potential partners”, said Cristiano Musso, Partner and Head of Europe at LifeSci Consulting.

For further information please contact:

Sundeep Aurora, Director, Theialife Sciences Limited
Phone: +91 9886676689

About LifeSci Consulting

LifeSci Consulting is a leading life sciences strategy consulting and transaction advisory firm. The firm leverages deep scientific acumen to assess commercial potential and positioning as well as to inform commercial strategy and market access. The firm’s transaction advisory practice focuses on securing non-dilutive capital and assets for clients through buy-side and sell-side strategic partnering transactions. For more information, please visit

About Theialife

Theialife is an innovative biopharmaceutical company focused on the discovery and development of a first-in-class drug targeting Myopia (near-sightedness).
The rising prevalence of Myopia in recent decades, especially in young children has reached an epidemic level across the world. Theialife is committed to developing innovative therapies that address unmet needs in Myopia management. Our novel Myopia control molecule is a first-in-class oral therapy for the treatment and management of Myopia progression in children. We have completed (a) preclinical development, (b) Phase 2 clinical trial in Denmark, and are in the process of initiating a Global Phase 3 clinical study. Our Product has been used clinically to prevent Myopia progression in more than 1100 Children over the last 12 years in Denmark. All IP related to The Dosage Form and related data is owned by Theialife. This first in class molecule will change the Myopia management landscape, especially for children with early-onset Myopia, who otherwise, given the limited therapies available, are bound to progress towards severe and sight threatening Myopia.
For more information, please visit

This website uses cookies

This website collects cookies to deliver better user experience